A 4-hour Profile of 17-hydroxyprogesterone in Salt-wasting Congenital Adrenal Hyperplasia: Is the Serial Monitoring Strategy Worth the Effort?

Objective: Since there exists no gold standard laboratory variable for adjustment of treatment in congenital adrenal hyperplasia (CAH), we aimed to assess the use of a 4-hour profile of serum 17-OHP to determine the most appropriate time and level of 17-OHP in predicting the metabolic control and evaluate the role of sex hormone-binding globulin (SHBG) in hyperandrogenemia.
Methods: This study included 16 children (9 girls,7 boys; median age 7 years) with salt-wasting CAH. Measurements for 17-OHP and cortisol were made from samples obtained before and 1,2,4 hours after the morning dose of hydrocortisone. Patients were designated to have poor metabolic control when androstenedione levels according to age and sex-specific reference intervals were high and annual height SDS changes were ⩾0.5.
Results: Premedication 17-OHP levels were strongly correlated with 17-OHP levels 1, 2, 4 hours after the morning dose (rs=0.929, p<0.01; rs=0.943, p<0.01; rs=0.835, p<0.01, respectively). 17-OHP profiles (0,1,2,4 hours) of poor (n=6) and good (n=10) metabolically controlled cases were similar. Among the patients with poor metabolic control, two cases had 17-OHP levels <2 ng/mL at all times. Remaining patients with poor metabolic control had 17-OHP levels above 104 ng/mL, 82 ng/mL, 14 ng/mL, and 4 ng/mL, for baseline and 1, 2, and 4 hours, respectively. Differences between the poor and well-controlled group were androstenedione levels with respect to upper limit of normal [1.8(1.5) and 0.5(1.5) ng/mL, respectively p=0.03], annual change in height SDS [0.7(0.2) and -0.03(0.8) SDS, respectively, p=0.001], and daily hydrocortisone doses [7 (6) and 16 (8) mg/m2/day, respectively, p=0.02]. Androstenedione and SHBG levels were negatively correlated in the pubertal children (rs=-0.7, p=0.04).
Conclusion: We conclude that (i)a 4-hour 17-OHP profile is not useful in predicting hyperandrogenemia, (ii)suppressed levels of 17-OHP do not always indicate overtreatment, (iii)reference intervals of 17-OHP for different time periods might be of importance, (iv) low hydrocortisone doses should be avoided, (v)SHBG could be used in pubertal children as an indicator of hyperandrogenemia.

Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate (17OHPC) in a Statewide Population-Based Cohort of Medicaid Enrollees

Objectives: The primary objective was to estimate the initiation and adherence rates of 17 α-hydroxyprogesterone caproate (17OHPC) among eligible mothers in a statewide population-based cohort of Medicaid enrollees. The secondary objectives were to (1) determine the association of maternal sociodemographic and clinical characteristics with 17OHPC utilization and (2) assess the real-world effectiveness of 17OHPC on recurrent preterm birth prevention and admission to neonatal intensive care unit (NICU).
Study design: This is a retrospective cohort study using a linked, longitudinal administrative dataset of birth certificates and medical assistance claims. Medicaid-enrolled mothers in Pennsylvania were included in this study if they had at least one singleton live birth from 2014 to 2016 following at least one spontaneous preterm birth. Maternal Medicaid claims were used to ascertain the use of 17OHPC from various manufacturers, including compounded formulations. Propensity score matching was used to create a covariate balance between 17OHPC treatment and comparison groups.
Results: We identified 4,781 Medicaid-covered 17OHPC-eligible pregnancies from 2014 to 2016 in Pennsylvania, 3.4% of all Medicaid-covered singleton live births. The population-based initiation rate was 28.5% among eligible pregnancies. Among initiators, 50% received ≥16 doses as recommended, while 10% received a single dose only. The severity of previous spontaneous preterm birth was the strongest predictor for the initiation and adherence of 17OHPC. In the matched treatment (n = 1,210) and comparison groups (n = 1,210), we found no evidence of 17OHPC effectiveness. The risks of recurrent preterm birth (relative risk [RR] 1.10, 95% confidence interval [CI] 0.97-1.24) and births admitted to NICU (RR 1.00, 95% CI 0.84-1.18) were similar in treated and comparison mothers.
Conclusion: The 17OHPC-eligible population represented 3.4% of singleton live births. Less than one-third of eligible mothers initiated treatment. Among initiators, 50% were treatment adherent. We found no difference in the risk of recurrent preterm birth or admission to NICU between treatment and comparison groups.

A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production

Objective: The rate of recurrent spontaneous preterm birth (PTB) was reduced by 33% in the Maternal-Fetal Medicine Unit (MFMU) Network trial of 17α-hydroxyprogesterone caproate (17-OHPC), but the mechanism of action, 17 years later, remains elusive. The robustness of the interleukin-10 (IL-10) response to lipopolysaccharide (LPS) stimulation of leukocytes in pregnant women with a prior PTB correlates with gestational age at delivery. This study sought to determine if there is a relationship between the concentration of 17-OHPC and response to LPS stimulation.
Study design: We performed a secondary analysis of data from the Omega-3 MFMU trial which evaluated the effectiveness of omega-3 fatty acid supplementation in reducing recurrent PTB. We utilized previously characterized data from a subanalyses of the Omega-3 trial of IL-10 and tumor necrosis factor alpha (TNF-α) levels from peripheral blood mononuclear cells stimulated with LPS. Blood was obtained from enrolled women at 16 to 22 weeks’ gestation (baseline) and 25 to 28 weeks’ gestation (posttreatment). All women received 17-OHPC and plasma 17-OHPC concentrations were measured at 25 to 28 weeks’ gestation. We analyzed these data to determine if there was a relationship between 17-OHPC concentration and cytokine production. We then performed an in vitro study to determine if 17-OHPC could directly alter cytokine production by THP-1-derived macrophages.
Results: In the clinical samples, we found that 17-OHPC plasma concentrations were correlated with the quantity of the LPS-stimulated production of IL-10. TNF-α production after LPS stimulation was unrelated to 17-OHPC concentration. In the in vitro study, we demonstrate a 17-OHPC concentration dependent increase in IL-10 production.
Conclusion: In women receiving 17-OHPC for PTB prevention, we demonstrate a relationship between plasma 17-OHPC and LPS-stimulated IL-10 production by circulating leukocytes. We also demonstrate that, in vitro, 17-OHPC treatment affects IL-10 production by LPS-stimulated macrophages. Collectively, these findings support an immunomodulatory mechanism of action of 17-OHPC in the prevention of recurrent PTB.
Product not found

In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring

Background: 17α-hydroxyprogesterone caproate (17-OHPC) is a synthetic progestogen initially approved in the 1950s to treat gynecological and obstetrical conditions. Despite repeated concerns of safety and short-term efficacy regarding the use of 17-OHPC for the prevention of preterm birth in pregnant women, little is known about long-term effects of 17-OHPC on health of offspring.
Objective: To examine the association between in utero exposure to 17-OHPC and risk of cancer in offspring.
Study design: The Child Health and Development Studies is a population-based cohort of more than 18,000 mother-child dyads receiving prenatal care in the Kaiser Foundation Health Plan (Oakland, California) between 1959 and 1966. Clinical information was abstracted from mothers’ medical records beginning six months prior to pregnancy through delivery. We identified the number and timing of 17-OHPC injections during pregnancy. Incident cancers diagnosed in offspring were ascertained through 2019 by linkage to the California Cancer Registry. We used Cox proportional hazards models to estimate adjusted hazard ratios (aHR) and their 95% confidence intervals, with follow-up time accrued from date of birth through date of cancer diagnosis, death, or last contact.
Results: 1,008 offspring were diagnosed with cancer over 730,817 person-years of follow-up. About 1.0% of offspring (n=234) were exposed in utero to 17-OHPC. Exposure in the first trimester was associated with increased risk of any cancer (aHR 2.57, 95% CI 1.59, 4.15), and risk increased with number of injections (1-2 injections: aHR 1.80, 95% CI 1.12,2.90; ≥3 injections: aHR 3.07, 95% CI 1.34, 7.05). Exposure in the second or third trimester conferred an additional risk for male (aHR 2.59, 95% CI 1.07, 6.28) but not female (aHR 0.30, 0.04, 1.11) offspring. Risk of colorectal (aHR 5.51, 95% CI 1.73, 17.59), prostate (aHR 5.10, 95% CI 1.24, 21.00), and pediatric brain (aHR 34.72, 95% CI 7.29, 164.33) cancer was higher in offspring first exposed to 17-OHPC in the first trimester compared to offspring not exposed.

Luminex Aries Controls

The ARIES SARS‑CoV‑2 Assay (EUA) is a real-time PCR-based in vitro diagnostic test that detects SARS‑CoV‑2 nucleic acid in nasopharyngeal swab (NPS) samples. Using the sample-to-answer ARIES System, the ARIES SARS‑CoV‑2 Assay delivers sensitive, rapid results in about two hours.

The ARIES SARS‑CoV‑2 Assay (EUA) offers:

  • Precise Results: A sample-to-answer test that enables targeted SARS‑CoV‑2 detection.
  • Fast Turnaround Time: Minimal hands-on time and an automated workflow deliver results in about two hours.
  • Robust Detection: Exonuclease-sensitive probes for the ORF1ab and N viral genes provide superior specificity.

Performance

The performance of the ARIES SARS‑CoV‑2 Assay was evaluated using blinded and randomized clinical specimens. The results are summarized in the table below.

*A mean Ct was calculated for the specimens where Ct was available.
Several replicates were negative for the ORF1ab gene, however, the N gene target was detected for these replicates, and the specimens were assigned a positive result.
An additional 30 contrived clinical positives and 30 clinical negative specimens were tested using purified SARS-CoV-2 viral genomic RNA (USA_WA1/2020 strain) obtained from World Reference Center for Emerging Viruses and Arboviruses (WRCEVA), and there were no changes to the assay performance between the old data and the new.

Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate cancer: scientific evidence and sharing of our experience.

Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate cancer: scientific evidence and sharing of our experience.
Presentation of the attention-grabbing case of a affected person affected by castrate-resistant prostate most cancers (CRPC) with bone metastasis, who obtained concomitant treatment with abiraterone acetate (AA) and radium-223. The affected person skilled important scientific enchancment in his high quality of life and ache aid after starting the aforementioned treatment, with out being affected by opposed toxicities.
Currently, the appropriate choice of sufferers to obtain radium-223 treatment remains to be a scientific problem in the case of CRPC with metastasis. In this text, we talk about the future prospects of this treatment, reviewing present evidence about concomitant therapies with radium-223 and its current state, primarily based upon the current suggestions from the Pharmacovigilance Risk Assessment Committee (PRAC), and the knowledge offered in the ERA-223 examine.
Based on our scientific expertise, we offer sensible orientation for the integration of this radiopharmaceutical in the therapeutic plan for this group of sufferers. We conclude, regardless of some of the constructive outcomes and our wonderful expertise, that it will be clever to attend for the outcomes of the scientific trials which are finding out the security and advantages of the combined use of radium-223 with new hormone therapies.
Bearing in thoughts that to this point, the solely revealed large-scale randomised trial that investigated the mixture of AR-axis-targeted remedy with Ra-223 is unfavourable, the harms of the mixture outweighed any advantages in ERA-223. Nonetheless, with a purpose to advocate whether or not or not this treatment must be used, it’s important to outline the affected person profile that would profit from this therapeutic possibility.
Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate cancer: scientific evidence and sharing of our experience.
Radium 223 combined with new hormone therapies for the treatment of castrate-resistant metastatic prostate most cancers: scientific evidence and sharing of our expertise.

Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases.

Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases.

Background: Brain radiotherapy is the usual remedy possibility for a number of mind metastases (BMs) from non-small cell lung most cancers (NSCLC), particularly in the absence of a driver mutation. However, the prognosis for such sufferers stays poor. Apatinib is a potent antiangiogenic compound directed on the vascular endothelial progress issue receptor-2 (VEGFR-2); nevertheless, to date, there are not any investigations of apatinib concurrent with mind radiotherapy for NSCLC sufferers with BMs.

We report a case of EGFR wild-type and ALK-negative lung adenocarcinoma affected person with a number of symptomatic BMs, who obtained apatinib along with mind radiation remedy. A positive oncologic consequence was achieved for each mind metastatic lesions and the first pulmonary tumor. Case Presentation: A 61-year-old feminine (by no means smoker) who initially offered with headache and dizziness was recognized with lung adenocarcinoma with a number of mind metastasis (cT2aN3M1b stage IV), and was unfavorable for EGFR and ALK.

The affected person refused to obtain chemotherapy and was solely amenable to mind radiotherapy and focused remedy. After approval from the institutional ethics committee, she underwent concurrent oral apatinib (500 mg/day) with complete mind radiation remedy (WBRT) (37.5Gy) with simultaneous in-field increase (49.5Gy) in 15 fractions with picture guided intensity-modulated radiotherapy.

Three weeks later, neurologic signs totally ceased and a partial response (PR) for the BMs with near-complete decision of peritumoral mind edema was achieved. Chest CT carried out on the identical time and confirmed shrinkage of the lung main with a PR.

The affected person suffered grade III oral mucositis one week after mind radiotherapy and refused additional apatinib. At 12 months after mind radiotherapy, the mind tumors remained properly managed. Conclusions: This is the primary identified documentation of a speedy medical response of apatinib concurrent with mind radiotherapy in a lung adenocarcinoma affected person with symptomatic a number of BMs. Apatinib mixed with mind radiotherapy could possibly be another remedy possibility for BMs from NSCLC, particularly for these with no driver mutation. Further medical trials are required to corroborate this discovery.

Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases.
Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases.

Pattern of Pediatric Supracondylar Fracture Operated at A Rural Teaching Hospital of Nepal: A Descriptive Cross-sectional Study.

Supracondylar fracture of humerus is likely one of the frequent pediatric fractures encountered in our every day medical observe. The goal of this examine is to decide the sample of supracondylar fracture operated at rural educating hospital of Jumla, Karnali Nepal.A descriptive cross sectional examine was carried out at Jumla, Karnali after Institutional Review Committee approval.

Operating room notes from 15 May 2017 to 16 November 2019 had been retrieved to collect the next data: sufferers tackle, age, intercourse, aspect, harm mechanism, displacement, neurovascular harm, concurrent accidents, preliminary administration by conventional bone setters, time between harm and surgical procedure, operative method.

NOD2 Antibody

1-CSB-PA015915GA01HU Cusabio
  • 716.40 EUR
  • 399.60 EUR
  • 150ul
  • 50ul
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB

NOD2 Antibody

1-CSB-PA881021LA01HU Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200

NOD2 Peptide

45-973P ProSci 0.1 mg 405.6 EUR
Description: (IN) CARD15 / NOD2 Peptide

NOD2 antibody

70R-18913 Fitzgerald 50 ul 522 EUR
Description: Rabbit polyclonal NOD2 antibody

NOD2 Antibody

37460-100ul SAB 100ul 302.4 EUR

NOD2 Antibody

24158-100ul SAB 100ul 468 EUR

NOD2 Antibody

24159-100ul SAB 100ul 468 EUR

Nod2 antibody

10R-6553 Fitzgerald 100 ug 522 EUR
Description: Rat monoclonal Nod2 antibody

NOD2 Antibody

2511-002mg ProSci 0.02 mg 206.18 EUR
Description: NOD2 Antibody: Apaf-1 and NOD1 are members of a new family, which are involved in the regulation of apoptosis and immune response. Each of them contains a caspase recruitment domain (CARD) and a nucleotide-binding oligomerization domain (NOD). A third member in this family was recently identified and designated NOD2. NOD2 interacts with RICK via a homophilic CARD-CARD interaction. NOD2 activates NF-κB, which is regulated by its carboxy-terminal leucine-rich repeat domain that acts as an intracellular receptor for components of bacteria. The variants of NOD2, either a frameshift or a missense, were associated with Crohn's disease that is a main type of chronic inflammatory bowel disease.

NOD2 Antibody

2511-01mg ProSci 0.1 mg 523.7 EUR
Description: NOD2 Antibody: Apaf-1 and NOD1 are members of a new family, which are involved in the regulation of apoptosis and immune response. Each of them contains a caspase recruitment domain (CARD) and a nucleotide-binding oligomerization domain (NOD). A third member in this family was recently identified and designated NOD2. NOD2 interacts with RICK via a homophilic CARD-CARD interaction. NOD2 activates NF-κB, which is regulated by its carboxy-terminal leucine-rich repeat domain that acts as an intracellular receptor for components of bacteria. The variants of NOD2, either a frameshift or a missense, were associated with Crohn's disease that is a main type of chronic inflammatory bowel disease.

NOD2 Peptide

2511P ProSci 0.05 mg 197.7 EUR
Description: (NT) NOD2 peptide

NOD2 Antibody

2513-002mg ProSci 0.02 mg 206.18 EUR
Description: NOD2 Antibody: Apaf-1 and NOD1 are members of a new family, which are involved in the regulation of apoptosis and immune response. Each of them contains a caspase recruitment domain (CARD) and a nucleotide-binding oligomerization domain (NOD). A third member in this family was recently identified and designated NOD2. NOD2 interacts with RICK via a homophilic CARD-CARD interaction. NOD2 activates NF-κB, which is regulated by its carboxy-terminal leucine-rich repeat domain that acts as an intracellular receptor for components of bacteria. The variants of NOD2, either a frameshift or a missense, were associated with Crohn's disease that is a main type of chronic inflammatory bowel disease.

NOD2 Antibody

2513-01mg ProSci 0.1 mg 523.7 EUR
Description: NOD2 Antibody: Apaf-1 and NOD1 are members of a new family, which are involved in the regulation of apoptosis and immune response. Each of them contains a caspase recruitment domain (CARD) and a nucleotide-binding oligomerization domain (NOD). A third member in this family was recently identified and designated NOD2. NOD2 interacts with RICK via a homophilic CARD-CARD interaction. NOD2 activates NF-κB, which is regulated by its carboxy-terminal leucine-rich repeat domain that acts as an intracellular receptor for components of bacteria. The variants of NOD2, either a frameshift or a missense, were associated with Crohn's disease that is a main type of chronic inflammatory bowel disease.

NOD2 Peptide

2513P ProSci 0.05 mg 197.7 EUR
Description: (CT) NOD2 peptide

anti-NOD2

YF-PA27607 Abfrontier 50 ug 435.6 EUR
Description: Mouse polyclonal to NOD2

NOD2 Antibody

R34436-100UG NSJ Bioreagents 100 ug 399 EUR

NOD2 Blocking Peptide

DF12125-BP Affbiotech 1mg 234 EUR

NOD2 Conjugated Antibody

C37460 SAB 100ul 476.4 EUR

NOD2 Rabbit pAb

A15992-100ul Abclonal 100 ul 369.6 EUR

NOD2 Rabbit pAb

A15992-200ul Abclonal 200 ul 550.8 EUR

NOD2 Rabbit pAb

A15992-20ul Abclonal 20 ul 219.6 EUR

NOD2 Rabbit pAb

A15992-50ul Abclonal 50 ul 267.6 EUR

Polyclonal NOD2 Antibody

APR06297G Leading Biology 0.1 mg 790.8 EUR
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 . This antibody is tested and proven to work in the following applications:

Polyclonal NOD2 Antibody

APR06298G Leading Biology 0.1 mg 790.8 EUR
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 . This antibody is tested and proven to work in the following applications:

Anti-NOD2 antibody

PAab05781 Lifescience Market 100 ug 494.4 EUR

Anti-NOD2 antibody

STJ118451 St John's Laboratory 100 µl 332.4 EUR

Human NOD2 shRNA Plasmid

20-abx961935 Abbexa
  • 961.20 EUR
  • 1345.20 EUR
  • 150 µg
  • 300 µg

NOD2 Antibody, HRP conjugated

1-CSB-PA881021LB01HU Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

NOD2 Antibody, FITC conjugated

1-CSB-PA881021LC01HU Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

NOD2 Antibody, Biotin conjugated

1-CSB-PA881021LD01HU Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

Anti-NOD2 (Card15) Antibody

A00087 BosterBio 50 ul 476.4 EUR
Description: Rabbit Polyclonal NOD2 (Card15) Antibody. Validated in IP, IHC, WB and tested in Human.

Mouse Nod2 ELISA KIT

ELI-44123m Lifescience Market 96 Tests 1038 EUR

Bovine NOD2 ELISA KIT

ELI-22273b Lifescience Market 96 Tests 1113.6 EUR

Human NOD2 ELISA KIT

ELI-23582h Lifescience Market 96 Tests 988.8 EUR

NOD2 ELISA KIT|Human

EF001273 Lifescience Market 96 Tests 826.8 EUR

TLR2 & NOD2-Based Adjuvant

VAdv-Ly0016 Creative Biolabs 5 mg 4016.4 EUR
Description: A TLR2 & NOD2-based vaccine adjuvant.

NOD2 ELISA Kit (Mouse) (OKCA01740)

OKCA01740 Aviva Systems Biology 96 Wells 1015.2 EUR
Description: Description of target: Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response (PubMed:22607974). Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages (PubMed:18511561).;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sanadwich ELISA;Sensitivity: 3.9 pg/mL

NOD2 ELISA Kit (Human) (OKAN06319)

OKAN06319 Aviva Systems Biology 96 Wells 950.4 EUR
Description: Description of target: This gene is a member of the Nod1/Apaf-1 family and encodes a protein with two caspase recruitment (CARD) domains and six leucine-rich repeats (LRRs). The protein is primarily expressed in the peripheral blood leukocytes. It plays a role in the immune response to intracellular bacterial lipopolysaccharides (LPS) by recognizing the muramyl dipeptide (MDP) derived from them and activating the NFKB protein. Mutations in this gene have been associated with Crohn disease and Blau syndrome. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.055 ng/mL

NOD2 ELISA Kit (Human) (OKCA02128)

OKCA02128 Aviva Systems Biology 96 Wells 999.6 EUR
Description: Description of target: Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 6.25 pg/mL

NOD2 ELISA Kit (Human) (OKCD02031)

OKCD02031 Aviva Systems Biology 96 Wells 997.2 EUR
Description: Description of target: Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich Immunoassay;Sensitivity: < 0.055 ng/mL

Nod2 ORF Vector (Rat) (pORF)

ORF071395 ABM 1.0 ug DNA 607.2 EUR

NOD2 ORF Vector (Human) (pORF)

ORF026166 ABM 1.0 ug DNA 486 EUR

Nod2 ORF Vector (Mouse) (pORF)

ORF051499 ABM 1.0 ug DNA 607.2 EUR

h NOD2 inducible lentiviral particles

LVP627 GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: NOD2 (nucleotide-binding oligomerization domain containing 2), [alternative names: ACUG; BLAU; CARD15; CD; CLR16.3; IBD1; NLRC2; NOD2B; PSORAS1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_022162.1. It also contains a RFP-Blasticidin dual selection marker.

pECMV-Nod2-m-FLAG Plasmid

PVT15371 Lifescience Market 2 ug 390 EUR

Anti-CARD15 / NOD2 (Internal) antibody

STJ70992 St John's Laboratory 100 µg 430.8 EUR

Polyclonal NOD2 / CARD15 Antibody (N-Terminus)

APR02524G Leading Biology 0.05mg 580.8 EUR
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 / CARD15 (N-Terminus). This antibody is tested and proven to work in the following applications:

Polyclonal NOD2 / CARD15 Antibody (C-Terminus)

APR02525G Leading Biology 0.05mg 580.8 EUR
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 / CARD15 (C-Terminus). This antibody is tested and proven to work in the following applications:

NOD2 sgRNA CRISPR Lentivector set (Human)

K1438601 ABM 3 x 1.0 ug 406.8 EUR

Nod2 sgRNA CRISPR Lentivector set (Mouse)

K4411601 ABM 3 x 1.0 ug 406.8 EUR

Nod2 sgRNA CRISPR Lentivector set (Rat)

K6718501 ABM 3 x 1.0 ug 406.8 EUR

Polyclonal Goat Anti-CARD15 / NOD2 (Internal) Antibody

APG00059G Leading Biology 0.1mg 580.8 EUR
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CARD15 / NOD2 (Internal) . This antibody is tested and proven to work in the following applications:

NOD2 Chemi-Luminescent ELISA Kit (Human) (OKCD03832)

OKCD03832 Aviva Systems Biology 96 Wells 1185.6 EUR
Description: Description of target: Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages .;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.0412 ng/mL

NOD2 sgRNA CRISPR Lentivector (Human) (Target 1)

K1438602 ABM 1.0 ug DNA 184.8 EUR

NOD2 sgRNA CRISPR Lentivector (Human) (Target 2)

K1438603 ABM 1.0 ug DNA 184.8 EUR

NOD2 sgRNA CRISPR Lentivector (Human) (Target 3)

K1438604 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K4411602 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K4411603 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K4411604 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Rat) (Target 1)

K6718502 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Rat) (Target 2)

K6718503 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Rat) (Target 3)

K6718504 ABM 1.0 ug DNA 184.8 EUR

NOD2 Protein Vector (Human) (pPB-C-His)

PV104662 ABM 500 ng 973.2 EUR

NOD2 Protein Vector (Human) (pPB-N-His)

PV104663 ABM 500 ng 973.2 EUR

NOD2 Protein Vector (Human) (pPM-C-HA)

PV104664 ABM 500 ng 973.2 EUR

NOD2 Protein Vector (Human) (pPM-C-His)

PV104665 ABM 500 ng 973.2 EUR

NOD2 Protein Vector (Rat) (pPB-C-His)

PV285578 ABM 500 ng 1399.2 EUR

NOD2 Protein Vector (Rat) (pPB-N-His)

PV285579 ABM 500 ng 1399.2 EUR

NOD2 Protein Vector (Rat) (pPM-C-HA)

PV285580 ABM 500 ng 1399.2 EUR

NOD2 Protein Vector (Rat) (pPM-C-His)

PV285581 ABM 500 ng 1399.2 EUR

NOD2 Protein Vector (Mouse) (pPB-C-His)

PV205994 ABM 500 ng 1278 EUR

NOD2 Protein Vector (Mouse) (pPB-N-His)

PV205995 ABM 500 ng 1278 EUR

NOD2 Protein Vector (Mouse) (pPM-C-HA)

PV205996 ABM 500 ng 1278 EUR

NOD2 Protein Vector (Mouse) (pPM-C-His)

PV205997 ABM 500 ng 1278 EUR

Nod2 3'UTR Luciferase Stable Cell Line

TU214065 ABM 1.0 ml Ask for price

Nod2 3'UTR GFP Stable Cell Line

TU264065 ABM 1.0 ml Ask for price

Nod2 3'UTR Luciferase Stable Cell Line

TU114191 ABM 1.0 ml Ask for price

Nod2 3'UTR GFP Stable Cell Line

TU164191 ABM 1.0 ml Ask for price

NOD2 3'UTR GFP Stable Cell Line

TU065801 ABM 1.0 ml 1636.8 EUR

NOD2 3'UTR Luciferase Stable Cell Line

TU015801 ABM 1.0 ml 1636.8 EUR

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody

20-abx114240 Abbexa
  • 878.40 EUR
  • 477.60 EUR
  • 150 ul
  • 50 ul

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody

20-abx302321 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody

abx235781-100ug Abbexa 100 ug 661.2 EUR

NOD2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV645601 ABM 1.0 ug DNA 1626 EUR

NOD2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV645605 ABM 1.0 ug DNA 1626 EUR

NOD2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV645606 ABM 1.0 ug DNA 1626 EUR

Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) Antibody

20-abx211027 Abbexa
  • 493.20 EUR
  • 360.00 EUR
  • 100 ul
  • 50 ul

Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) Antibody

20-abx339338 Abbexa
  • 493.20 EUR
  • 360.00 EUR
  • 100 ul
  • 50 ul

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody (HRP)

20-abx316579 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody (FITC)

20-abx316580 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody (Biotin)

20-abx316581 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

NOD2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K1438605 ABM 3 x 1.0 ug 451.2 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K4411605 ABM 3 x 1.0 ug 451.2 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K6718505 ABM 3 x 1.0 ug 451.2 EUR

Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) ELISA kit

CSB-EL015915HU-24T Cusabio 1 plate of 24 wells 198 EUR
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) in samples from serum, plasma, asciticfluid, tissue homogenates, cell lysates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) ELISA kit

1-CSB-EL015915HU Cusabio
  • 964.80 EUR
  • 6118.80 EUR
  • 3244.80 EUR
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) in samples from serum, plasma, asciticfluid, tissue homogenates, cell lysates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit

20-abx190892 Abbexa
  • 9493.20 EUR
  • 5058.00 EUR
  • 1167.60 EUR
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

20-abx258642 Abbexa
  • 8853.60 EUR
  • 4719.60 EUR
  • 1093.20 EUR
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

NOD2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV645602 ABM 1.0 ug DNA 1626 EUR

NOD2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV645603 ABM 1.0 ug DNA 1695.6 EUR

NOD2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV645604 ABM 1.0 ug DNA 1695.6 EUR

NOD2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K1438606 ABM 1.0 ug DNA 200.4 EUR

NOD2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K1438607 ABM 1.0 ug DNA 200.4 EUR

NOD2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K1438608 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K4411606 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K4411607 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K4411608 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K6718506 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K6718507 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K6718508 ABM 1.0 ug DNA 200.4 EUR

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

SEK295Hu-10x96wellstestplate Cloud-Clone 10x96-wells test plate 5677.8 EUR
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

SEK295Hu-1x48wellstestplate Cloud-Clone 1x48-wells test plate 572.76 EUR
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

SEK295Hu-1x96wellstestplate Cloud-Clone 1x96-wells test plate 766.8 EUR
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

SEK295Hu-5x96wellstestplate Cloud-Clone 5x96-wells test plate 3090.6 EUR
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

4-SEK295Hu Cloud-Clone
  • 5738.40 EUR
  • 3031.20 EUR
  • 768.00 EUR
  • 10 plates of 96 wells
  • 5 plates of 96 wells
  • 1 plate of 96 wells
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in samples from tissue homogenates, cell lysates and other biological fluids with no significant corss-reactivity with analogues from other species.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit

SCK295Hu-10x96wellstestplate Cloud-Clone 10x96-wells test plate 6777.36 EUR
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit

SCK295Hu-1x48wellstestplate Cloud-Clone 1x48-wells test plate 663.31 EUR
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit

SCK295Hu-1x96wellstestplate Cloud-Clone 1x96-wells test plate 896.16 EUR
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit

SCK295Hu-5x96wellstestplate Cloud-Clone 5x96-wells test plate 3672.72 EUR
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit

4-SCK295Hu Cloud-Clone
  • 6837.60 EUR
  • 3673.20 EUR
  • 896.40 EUR
  • 10 plates of 96 wells
  • 5 plates of 96 wells
  • 1 plate of 96 wells
Description: Double-antibody Sandwich chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)Tissue homogenates, cell lysates and other biological fluids

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 ELISA Kit (NOD2)

RK01942 Abclonal 96 Tests 625.2 EUR

ELISA kit for Human NOD2 (Nucleotide Binding Oligomerization Domain Containing Protein 2)

ELK5352 ELK Biotech 1 plate of 96 wells 518.4 EUR
Description: A sandwich ELISA kit for detection of Nucleotide Binding Oligomerization Domain Containing Protein 2 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Data evaluation was performed utilizing Statistical Package for Social Sciences model 20.Left aspect predominated with 88 (63.7%) and extension kind was frequent in 135 (97.8%). Thirteen (9.4%) sufferers had been initially managed by conventional bonesetters. A complete of 138 kids underwent operative fixation with imply age of seven.47 years and gender ratio of two:1 boy to woman.

Fall from cliff, ladders and rooftops had been the prevailing explanation for harm 73 (52.8%). Average time between harm and surgical procedure was 5.2 days. Closed discount was performed in 100 (72.4%) sufferers whereas open discount was crucial in 38 (27.5%) sufferers.Closed extension kind pediatric supracondylar fracture was frequent in this examine. Fall from cliff, rooftop and ladder are the most important explanation for fracture. Delayed presentation and preliminary administration of the fracture by the standard bonesetters makes supracondylar fracture tougher in useful resource restricted setting like ours.

Patterns of Metastasis in Merkel Cell Carcinoma.

Patterns of Metastasis in Merkel Cell Carcinoma.

Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine malignancy with a propensity for regional and distant unfold. Because of the relative infrequency of this illness, the patterns of metastasis in MCC are understudied.Patients with American Joint Committee on Cancer (eighth version) stage I-IV MCC handled at our establishment were recognized (1/1/2008-2/28/2018). The first web site of metastasis was categorized as regional [regional lymph node (LN) basin, in-transit] or distant. Distant metastasis-free (DMFS) and MCC-specific (MSS) survival have been estimated.

Results

Of 133 sufferers, 64 (48%) had stage I, 13 (10%) stage II, 48 (36%) stage III, and eight (6%) stage IV illness at presentation. The median follow-up time in sufferers who remained alive was 36 (interquartile vary 20-66) months. Regional or distant metastases developed in 78 (59%) sufferers. The first web site was regional in 87%, together with 73% with remoted LN involvement, and distant in 13%. Thirty-seven (28%) sufferers ultimately developed distant illness, which mostly concerned the belly viscera (51%) and distant LNs (46%) first.

The lung (0%) and mind (3%) have been not often the primary distant websites. Stage III MCC at presentation was considerably related to worse DMFS (hazard ratio 4.87, P = 0.001) and stage IV illness with worse MSS (hazard ratio 6.30, P = 0.002).Regional LN metastasis is the commonest first metastatic occasion in MCC, confirming the significance of nodal analysis. Distant illness unfold seems to have a predilection for sure websites. Understanding these patterns might assist to information surveillance methods.

Patterns of Metastasis in Merkel Cell Carcinoma.
Patterns of Metastasis in Merkel Cell Carcinoma.

Coronavirus Disease-19 (COVID-19) related to extreme acute pancreatitis: Case report on three relations.

Abdominal ache is one of the recognized signs related to coronavirus illness 2019. Little is thought in regards to the growth of acute pancreatitis as a complication of extreme acute respiratory syndrome coronavirus 2 an infection. This case report describes the presentation of acute pancreatitis in two of three relations with extreme COVID-19 an infection.

Data have been collected from three relations admitted with COVID-19 to the intensive care unit in March 2020. This research was reviewed and accepted by the native information and ethics committee (31-1521-253).

NOD2 Antibody

1-CSB-PA015915GA01HU Cusabio
  • 716.40 EUR
  • 399.60 EUR
  • 150ul
  • 50ul
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB

NOD2 Antibody

1-CSB-PA881021LA01HU Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200

NOD2 Peptide

45-973P ProSci 0.1 mg 405.6 EUR
Description: (IN) CARD15 / NOD2 Peptide

NOD2 antibody

70R-18913 Fitzgerald 50 ul 522 EUR
Description: Rabbit polyclonal NOD2 antibody

NOD2 Antibody

37460-100ul SAB 100ul 302.4 EUR

NOD2 Antibody

24158-100ul SAB 100ul 468 EUR

NOD2 Antibody

24159-100ul SAB 100ul 468 EUR

Nod2 antibody

10R-6553 Fitzgerald 100 ug 522 EUR
Description: Rat monoclonal Nod2 antibody

NOD2 Antibody

2511-002mg ProSci 0.02 mg 206.18 EUR
Description: NOD2 Antibody: Apaf-1 and NOD1 are members of a new family, which are involved in the regulation of apoptosis and immune response. Each of them contains a caspase recruitment domain (CARD) and a nucleotide-binding oligomerization domain (NOD). A third member in this family was recently identified and designated NOD2. NOD2 interacts with RICK via a homophilic CARD-CARD interaction. NOD2 activates NF-κB, which is regulated by its carboxy-terminal leucine-rich repeat domain that acts as an intracellular receptor for components of bacteria. The variants of NOD2, either a frameshift or a missense, were associated with Crohn's disease that is a main type of chronic inflammatory bowel disease.

NOD2 Antibody

2511-01mg ProSci 0.1 mg 523.7 EUR
Description: NOD2 Antibody: Apaf-1 and NOD1 are members of a new family, which are involved in the regulation of apoptosis and immune response. Each of them contains a caspase recruitment domain (CARD) and a nucleotide-binding oligomerization domain (NOD). A third member in this family was recently identified and designated NOD2. NOD2 interacts with RICK via a homophilic CARD-CARD interaction. NOD2 activates NF-κB, which is regulated by its carboxy-terminal leucine-rich repeat domain that acts as an intracellular receptor for components of bacteria. The variants of NOD2, either a frameshift or a missense, were associated with Crohn's disease that is a main type of chronic inflammatory bowel disease.

NOD2 Peptide

2511P ProSci 0.05 mg 197.7 EUR
Description: (NT) NOD2 peptide

NOD2 Antibody

2513-002mg ProSci 0.02 mg 206.18 EUR
Description: NOD2 Antibody: Apaf-1 and NOD1 are members of a new family, which are involved in the regulation of apoptosis and immune response. Each of them contains a caspase recruitment domain (CARD) and a nucleotide-binding oligomerization domain (NOD). A third member in this family was recently identified and designated NOD2. NOD2 interacts with RICK via a homophilic CARD-CARD interaction. NOD2 activates NF-κB, which is regulated by its carboxy-terminal leucine-rich repeat domain that acts as an intracellular receptor for components of bacteria. The variants of NOD2, either a frameshift or a missense, were associated with Crohn's disease that is a main type of chronic inflammatory bowel disease.

NOD2 Antibody

2513-01mg ProSci 0.1 mg 523.7 EUR
Description: NOD2 Antibody: Apaf-1 and NOD1 are members of a new family, which are involved in the regulation of apoptosis and immune response. Each of them contains a caspase recruitment domain (CARD) and a nucleotide-binding oligomerization domain (NOD). A third member in this family was recently identified and designated NOD2. NOD2 interacts with RICK via a homophilic CARD-CARD interaction. NOD2 activates NF-κB, which is regulated by its carboxy-terminal leucine-rich repeat domain that acts as an intracellular receptor for components of bacteria. The variants of NOD2, either a frameshift or a missense, were associated with Crohn's disease that is a main type of chronic inflammatory bowel disease.

NOD2 Peptide

2513P ProSci 0.05 mg 197.7 EUR
Description: (CT) NOD2 peptide

anti-NOD2

YF-PA27607 Abfrontier 50 ug 435.6 EUR
Description: Mouse polyclonal to NOD2

NOD2 Antibody

R34436-100UG NSJ Bioreagents 100 ug 399 EUR

NOD2 Blocking Peptide

DF12125-BP Affbiotech 1mg 234 EUR

NOD2 Conjugated Antibody

C37460 SAB 100ul 476.4 EUR

NOD2 Rabbit pAb

A15992-100ul Abclonal 100 ul 369.6 EUR

NOD2 Rabbit pAb

A15992-200ul Abclonal 200 ul 550.8 EUR

NOD2 Rabbit pAb

A15992-20ul Abclonal 20 ul 219.6 EUR

NOD2 Rabbit pAb

A15992-50ul Abclonal 50 ul 267.6 EUR

Polyclonal NOD2 Antibody

APR06297G Leading Biology 0.1 mg 790.8 EUR
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 . This antibody is tested and proven to work in the following applications:

Polyclonal NOD2 Antibody

APR06298G Leading Biology 0.1 mg 790.8 EUR
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 . This antibody is tested and proven to work in the following applications:

Anti-NOD2 antibody

PAab05781 Lifescience Market 100 ug 494.4 EUR

Anti-NOD2 antibody

STJ118451 St John's Laboratory 100 µl 332.4 EUR

Human NOD2 shRNA Plasmid

20-abx961935 Abbexa
  • 961.20 EUR
  • 1345.20 EUR
  • 150 µg
  • 300 µg

NOD2 Antibody, HRP conjugated

1-CSB-PA881021LB01HU Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

NOD2 Antibody, FITC conjugated

1-CSB-PA881021LC01HU Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

NOD2 Antibody, Biotin conjugated

1-CSB-PA881021LD01HU Cusabio
  • 380.40 EUR
  • 402.00 EUR
  • 100ug
  • 50ug
Description: A polyclonal antibody against NOD2. Recognizes NOD2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

Anti-NOD2 (Card15) Antibody

A00087 BosterBio 50 ul 476.4 EUR
Description: Rabbit Polyclonal NOD2 (Card15) Antibody. Validated in IP, IHC, WB and tested in Human.

Mouse Nod2 ELISA KIT

ELI-44123m Lifescience Market 96 Tests 1038 EUR

Bovine NOD2 ELISA KIT

ELI-22273b Lifescience Market 96 Tests 1113.6 EUR

Human NOD2 ELISA KIT

ELI-23582h Lifescience Market 96 Tests 988.8 EUR

NOD2 ELISA KIT|Human

EF001273 Lifescience Market 96 Tests 826.8 EUR

TLR2 & NOD2-Based Adjuvant

VAdv-Ly0016 Creative Biolabs 5 mg 4016.4 EUR
Description: A TLR2 & NOD2-based vaccine adjuvant.

NOD2 ELISA Kit (Mouse) (OKCA01740)

OKCA01740 Aviva Systems Biology 96 Wells 1015.2 EUR
Description: Description of target: Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response (PubMed:22607974). Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages (PubMed:18511561).;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sanadwich ELISA;Sensitivity: 3.9 pg/mL

NOD2 ELISA Kit (Human) (OKAN06319)

OKAN06319 Aviva Systems Biology 96 Wells 950.4 EUR
Description: Description of target: This gene is a member of the Nod1/Apaf-1 family and encodes a protein with two caspase recruitment (CARD) domains and six leucine-rich repeats (LRRs). The protein is primarily expressed in the peripheral blood leukocytes. It plays a role in the immune response to intracellular bacterial lipopolysaccharides (LPS) by recognizing the muramyl dipeptide (MDP) derived from them and activating the NFKB protein. Mutations in this gene have been associated with Crohn disease and Blau syndrome. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.055 ng/mL

NOD2 ELISA Kit (Human) (OKCA02128)

OKCA02128 Aviva Systems Biology 96 Wells 999.6 EUR
Description: Description of target: Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 6.25 pg/mL

NOD2 ELISA Kit (Human) (OKCD02031)

OKCD02031 Aviva Systems Biology 96 Wells 997.2 EUR
Description: Description of target: Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich Immunoassay;Sensitivity: < 0.055 ng/mL

Nod2 ORF Vector (Rat) (pORF)

ORF071395 ABM 1.0 ug DNA 607.2 EUR

NOD2 ORF Vector (Human) (pORF)

ORF026166 ABM 1.0 ug DNA 486 EUR

Nod2 ORF Vector (Mouse) (pORF)

ORF051499 ABM 1.0 ug DNA 607.2 EUR

h NOD2 inducible lentiviral particles

LVP627 GenTarget 1x107 IFU/ml x 200ul 541.2 EUR
Description: Pre-made over-expression lentivirus for expressing human target: NOD2 (nucleotide-binding oligomerization domain containing 2), [alternative names: ACUG; BLAU; CARD15; CD; CLR16.3; IBD1; NLRC2; NOD2B; PSORAS1]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_022162.1. It also contains a RFP-Blasticidin dual selection marker.

pECMV-Nod2-m-FLAG Plasmid

PVT15371 Lifescience Market 2 ug 390 EUR

Anti-CARD15 / NOD2 (Internal) antibody

STJ70992 St John's Laboratory 100 µg 430.8 EUR

Polyclonal NOD2 / CARD15 Antibody (N-Terminus)

APR02524G Leading Biology 0.05mg 580.8 EUR
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 / CARD15 (N-Terminus). This antibody is tested and proven to work in the following applications:

Polyclonal NOD2 / CARD15 Antibody (C-Terminus)

APR02525G Leading Biology 0.05mg 580.8 EUR
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human NOD2 / CARD15 (C-Terminus). This antibody is tested and proven to work in the following applications:

NOD2 sgRNA CRISPR Lentivector set (Human)

K1438601 ABM 3 x 1.0 ug 406.8 EUR

Nod2 sgRNA CRISPR Lentivector set (Mouse)

K4411601 ABM 3 x 1.0 ug 406.8 EUR

Nod2 sgRNA CRISPR Lentivector set (Rat)

K6718501 ABM 3 x 1.0 ug 406.8 EUR

Polyclonal Goat Anti-CARD15 / NOD2 (Internal) Antibody

APG00059G Leading Biology 0.1mg 580.8 EUR
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CARD15 / NOD2 (Internal) . This antibody is tested and proven to work in the following applications:

NOD2 Chemi-Luminescent ELISA Kit (Human) (OKCD03832)

OKCD03832 Aviva Systems Biology 96 Wells 1185.6 EUR
Description: Description of target: Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages .;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.0412 ng/mL

NOD2 sgRNA CRISPR Lentivector (Human) (Target 1)

K1438602 ABM 1.0 ug DNA 184.8 EUR

NOD2 sgRNA CRISPR Lentivector (Human) (Target 2)

K1438603 ABM 1.0 ug DNA 184.8 EUR

NOD2 sgRNA CRISPR Lentivector (Human) (Target 3)

K1438604 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K4411602 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K4411603 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K4411604 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Rat) (Target 1)

K6718502 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Rat) (Target 2)

K6718503 ABM 1.0 ug DNA 184.8 EUR

Nod2 sgRNA CRISPR Lentivector (Rat) (Target 3)

K6718504 ABM 1.0 ug DNA 184.8 EUR

NOD2 Protein Vector (Human) (pPB-C-His)

PV104662 ABM 500 ng 973.2 EUR

NOD2 Protein Vector (Human) (pPB-N-His)

PV104663 ABM 500 ng 973.2 EUR

NOD2 Protein Vector (Human) (pPM-C-HA)

PV104664 ABM 500 ng 973.2 EUR

NOD2 Protein Vector (Human) (pPM-C-His)

PV104665 ABM 500 ng 973.2 EUR

NOD2 Protein Vector (Rat) (pPB-C-His)

PV285578 ABM 500 ng 1399.2 EUR

NOD2 Protein Vector (Rat) (pPB-N-His)

PV285579 ABM 500 ng 1399.2 EUR

NOD2 Protein Vector (Rat) (pPM-C-HA)

PV285580 ABM 500 ng 1399.2 EUR

NOD2 Protein Vector (Rat) (pPM-C-His)

PV285581 ABM 500 ng 1399.2 EUR

NOD2 Protein Vector (Mouse) (pPB-C-His)

PV205994 ABM 500 ng 1278 EUR

NOD2 Protein Vector (Mouse) (pPB-N-His)

PV205995 ABM 500 ng 1278 EUR

NOD2 Protein Vector (Mouse) (pPM-C-HA)

PV205996 ABM 500 ng 1278 EUR

NOD2 Protein Vector (Mouse) (pPM-C-His)

PV205997 ABM 500 ng 1278 EUR

Nod2 3'UTR Luciferase Stable Cell Line

TU214065 ABM 1.0 ml Ask for price

Nod2 3'UTR GFP Stable Cell Line

TU264065 ABM 1.0 ml Ask for price

Nod2 3'UTR Luciferase Stable Cell Line

TU114191 ABM 1.0 ml Ask for price

Nod2 3'UTR GFP Stable Cell Line

TU164191 ABM 1.0 ml Ask for price

NOD2 3'UTR GFP Stable Cell Line

TU065801 ABM 1.0 ml 1636.8 EUR

NOD2 3'UTR Luciferase Stable Cell Line

TU015801 ABM 1.0 ml 1636.8 EUR

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody

20-abx114240 Abbexa
  • 878.40 EUR
  • 477.60 EUR
  • 150 ul
  • 50 ul

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody

20-abx302321 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody

abx235781-100ug Abbexa 100 ug 661.2 EUR

NOD2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)

LV645601 ABM 1.0 ug DNA 1626 EUR

NOD2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)

LV645605 ABM 1.0 ug DNA 1626 EUR

NOD2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)

LV645606 ABM 1.0 ug DNA 1626 EUR

Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) Antibody

20-abx211027 Abbexa
  • 493.20 EUR
  • 360.00 EUR
  • 100 ul
  • 50 ul

Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) Antibody

20-abx339338 Abbexa
  • 493.20 EUR
  • 360.00 EUR
  • 100 ul
  • 50 ul

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody (HRP)

20-abx316579 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody (FITC)

20-abx316580 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Nucleotide Binding Oligomerization Domain Containing 2 (NOD2) Antibody (Biotin)

20-abx316581 Abbexa
  • 493.20 EUR
  • 2214.00 EUR
  • 718.80 EUR
  • 218.40 EUR
  • 360.00 EUR
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

NOD2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)

K1438605 ABM 3 x 1.0 ug 451.2 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)

K4411605 ABM 3 x 1.0 ug 451.2 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat)

K6718505 ABM 3 x 1.0 ug 451.2 EUR

Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) ELISA kit

CSB-EL015915HU-24T Cusabio 1 plate of 24 wells 198 EUR
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) in samples from serum, plasma, asciticfluid, tissue homogenates, cell lysates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) ELISA kit

1-CSB-EL015915HU Cusabio
  • 964.80 EUR
  • 6118.80 EUR
  • 3244.80 EUR
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Human Nucleotide-binding oligomerization domain-containing protein 2(NOD2) in samples from serum, plasma, asciticfluid, tissue homogenates, cell lysates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit

20-abx190892 Abbexa
  • 9493.20 EUR
  • 5058.00 EUR
  • 1167.60 EUR
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

20-abx258642 Abbexa
  • 8853.60 EUR
  • 4719.60 EUR
  • 1093.20 EUR
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

NOD2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)

LV645602 ABM 1.0 ug DNA 1626 EUR

NOD2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)

LV645603 ABM 1.0 ug DNA 1695.6 EUR

NOD2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)

LV645604 ABM 1.0 ug DNA 1695.6 EUR

NOD2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)

K1438606 ABM 1.0 ug DNA 200.4 EUR

NOD2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)

K1438607 ABM 1.0 ug DNA 200.4 EUR

NOD2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)

K1438608 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)

K4411606 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2)

K4411607 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)

K4411608 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1)

K6718506 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)

K6718507 ABM 1.0 ug DNA 200.4 EUR

Nod2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3)

K6718508 ABM 1.0 ug DNA 200.4 EUR

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

SEK295Hu-10x96wellstestplate Cloud-Clone 10x96-wells test plate 5677.8 EUR
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

SEK295Hu-1x48wellstestplate Cloud-Clone 1x48-wells test plate 572.76 EUR
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

SEK295Hu-1x96wellstestplate Cloud-Clone 1x96-wells test plate 766.8 EUR
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

SEK295Hu-5x96wellstestplate Cloud-Clone 5x96-wells test plate 3090.6 EUR
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) ELISA Kit

4-SEK295Hu Cloud-Clone
  • 5738.40 EUR
  • 3031.20 EUR
  • 768.00 EUR
  • 10 plates of 96 wells
  • 5 plates of 96 wells
  • 1 plate of 96 wells
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in samples from tissue homogenates, cell lysates and other biological fluids with no significant corss-reactivity with analogues from other species.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit

SCK295Hu-10x96wellstestplate Cloud-Clone 10x96-wells test plate 6777.36 EUR
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit

SCK295Hu-1x48wellstestplate Cloud-Clone 1x48-wells test plate 663.31 EUR
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit

SCK295Hu-1x96wellstestplate Cloud-Clone 1x96-wells test plate 896.16 EUR
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)CLIA Kit

SCK295Hu-5x96wellstestplate Cloud-Clone 5x96-wells test plate 3672.72 EUR
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) in Tissue homogenates, cell lysates and other biological fluids.

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2) CLIA Kit

4-SCK295Hu Cloud-Clone
  • 6837.60 EUR
  • 3673.20 EUR
  • 896.40 EUR
  • 10 plates of 96 wells
  • 5 plates of 96 wells
  • 1 plate of 96 wells
Description: Double-antibody Sandwich chemiluminescent immunoassay for detection of Human Nucleotide Binding Oligomerization Domain Containing Protein 2 (NOD2)Tissue homogenates, cell lysates and other biological fluids

Human Nucleotide Binding Oligomerization Domain Containing Protein 2 ELISA Kit (NOD2)

RK01942 Abclonal 96 Tests 625.2 EUR

ELISA kit for Human NOD2 (Nucleotide Binding Oligomerization Domain Containing Protein 2)

ELK5352 ELK Biotech 1 plate of 96 wells 518.4 EUR
Description: A sandwich ELISA kit for detection of Nucleotide Binding Oligomerization Domain Containing Protein 2 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Two of the three relations have been recognized with acute pancreatitis related to SARS-CoV-2. Other causes of acute pancreatitis have been excluded for each sufferers (together with alcohol, biliary obstruction/gall stones, medication, trauma, hypertriglyceridemia, hypercalcemia, and hypotension).These circumstances spotlight acute pancreatitis as a complication related to COVID-19 and underlines the significance of measuring pancreas-specific plasma amylase in sufferers with COVID-19 and belly ache.